《2015年HIV-1耐药性突变更新》
2015 Update of the Drug Resistance Mutations in HIV-1.
作者信息
Wensing Annemarie M, Calvez Vincent, Günthard Huldrych F, Johnson Victoria A, Paredes Roger, Pillay Deenan, Shafer Robert W, Richman Douglas D
机构信息
University Medical Center Utrecht, The Netherlands.
Pierre et Marie Curie University and Pitié-Salpêtrière Hospital, Paris, France.
出版信息
Top Antivir Med. 2015 Oct-Nov;23(4):132-41.
Abstract
The 2015 edition of the IAS-USA drug resistance mutations list updates the figures last published in July 2014. The mutations listed are those that have been identified by specific criteria for evidence and drugs described. The figures are designed to assist practitioners in identifying key mutations associated with resistance to antiretroviral drugs and, therefore, in making clinical decisions regarding antiretroviral therapy.
摘要
美国抗逆转录病毒学会（IAS-USA）2015年版耐药突变列表更新了上次于2014年7月发布的数据。列出的突变是根据针对所述证据和药物的特定标准确定的。这些数据旨在帮助从业者识别与抗逆转录病毒药物耐药性相关的关键突变，从而在抗逆转录病毒治疗方面做出临床决策。
相似文献
1
2015 Update of the Drug Resistance Mutations in HIV-1.《2015年HIV-1耐药性突变更新》
Top Antivir Med. 2015 Oct-Nov;23(4):132-41.
2
2017 Update of the Drug Resistance Mutations in HIV-1.《2017年HIV-1耐药性突变更新》
Top Antivir Med. 2016 Dec;24(4):132-133.
3
2019 update of the drug resistance mutations in HIV-1.2019年人类免疫缺陷病毒1型耐药性突变的更新情况。
Top Antivir Med. 2019 Sep;27(3):111-121.
4
Update of the Drug Resistance Mutations in HIV-1.人类免疫缺陷病毒1型耐药突变的更新
Top HIV Med. 2008 Dec;16(5):138-45.
5
2022 update of the drug resistance mutations in HIV-1.2022 年 HIV-1 耐药突变更新。
Top Antivir Med. 2022 Oct;30(4):559-574.
6
Update of the drug resistance mutations in HIV-1: Fall 2006.2006年秋季HIV-1耐药性突变更新
Top HIV Med. 2006 Aug-Sep;14(3):125-30.
7
Update of the Drug Resistance Mutations in HIV-1: 2005.2005年HIV-1耐药性突变的更新情况。
Top HIV Med. 2005 Mar-Apr;13(1):51-7.
8
Update of the drug resistance mutations in HIV-1: Fall 2005.2005年秋季HIV-1耐药性突变的更新情况。
Top HIV Med. 2005 Oct-Nov;13(4):125-31.
9
2011 update of the drug resistance mutations in HIV-1.2011年人类免疫缺陷病毒1型耐药性突变的更新情况
Top Antivir Med. 2011 Nov;19(4):156-64.
10
Short communication: low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia.简短通讯：马来西亚初治的1型艾滋病毒患者中基因型耐药突变的低流行率
AIDS Res Hum Retroviruses. 2006 Feb;22(2):121-4. doi: 10.1089/aid.2006.22.121.
引用本文的文献
1
Sub- and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study.乌干达儿童中依非韦伦血浆浓度低于和高于治疗水平且存在HIV治疗失败风险主要由基因因素导致：前瞻性GENEFA队列研究
Br J Clin Pharmacol. 2025 Feb;91(2):464-478. doi: 10.1111/bcp.16272. Epub 2024 Oct 8.
2
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.扩展多变量模型以辅助长效卡替拉韦+利匹韦林治疗的患者选择：与病毒学失败相关的患者、药物浓度和病毒因素组合的临床效用。
Clin Infect Dis. 2023 Nov 17;77(10):1423-1431. doi: 10.1093/cid/ciad370.
3
Evaluating whole HIV-1 genome sequence for estimation of incidence and migration in a rural South African community.评估完整的HIV-1基因组序列以估计南非农村社区的发病率和人口迁移情况。
Wellcome Open Res. 2022 Jun 21;7:174. doi: 10.12688/wellcomeopenres.17891.1. eCollection 2022.
4
Prevalence and Structure of HIV-1 Drug Resistance to Antiretrovirals in the Volga Federal District in 2008-2019.2008-2019 年伏尔加联邦区抗逆转录病毒药物的 HIV-1 耐药性的流行率和结构。
Viruses. 2022 Aug 27;14(9):1898. doi: 10.3390/v14091898.
5
Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria.深度测序 HIV-1 揭示了尼日利亚一线抗逆转录病毒治疗失败后广泛的亚型变异和耐药性。
J Antimicrob Chemother. 2022 Feb 2;77(2):474-482. doi: 10.1093/jac/dkab385.
6
Non-B variants of HIV-1 in San Francisco, California.加利福尼亚州旧金山的 HIV-1 非 B 变异体。
Infect Genet Evol. 2021 Jun;90:104677. doi: 10.1016/j.meegid.2020.104677. Epub 2020 Dec 13.
7
A retrospective descriptive investigation of adult patients receiving third-line antiretroviral therapy in the North West province, South Africa.对南非西北省接受三线抗逆转录病毒治疗的成年患者进行的回顾性描述性调查。
Afr Health Sci. 2020 Jun;20(2):549-559. doi: 10.4314/ahs.v20i2.2.
8
Analysis of sequence diversity and selection pressure in HIV-1 clade C gp41 from India.印度HIV-1 C亚型gp41的序列多样性与选择压力分析。
Virusdisease. 2020 Sep;31(3):277-291. doi: 10.1007/s13337-020-00595-x. Epub 2020 May 12.
9
Polymorphisms and drug resistance analysis of HIV-1 isolates from patients on first line antiretroviral therapy (ART) in South-eastern Nigeria.尼日利亚东南部一线抗逆转录病毒治疗（ART）患者 HIV-1 分离株的多态性和耐药性分析。
PLoS One. 2020 Apr 8;15(4):e0231031. doi: 10.1371/journal.pone.0231031. eCollection 2020.
10
Prevalence of acquired drug resistance mutations in antiretroviral- experiencing subjects from 2012 to 2017 in Hunan Province of central South China.2012 年至 2017 年中国中南地区湖南省接受抗逆转录病毒治疗的患者中获得性耐药突变的流行情况。
Virol J. 2020 Mar 17;17(1):38. doi: 10.1186/s12985-020-01311-3.
本文引用的文献
1
2014 Update of the drug resistance mutations in HIV-1.2014年人类免疫缺陷病毒1型耐药性突变更新
Top Antivir Med. 2014 Jun-Jul;22(3):642-50.
2
Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.成人 HIV 感染的抗逆转录病毒治疗：美国国际抗病毒学会 2014 年推荐意见。
JAMA. 2014;312(4):410-25. doi: 10.1001/jama.2014.8722.
3
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.多替拉韦对比雷特格韦在有 HIV 的抗逆转录病毒治疗经验、整合酶抑制剂初治成人中的疗效：来自随机、双盲、非劣效性 SAILING 研究的第 48 周结果。
Lancet. 2013 Aug 24;382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0. Epub 2013 Jul 3.
4
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.原发性依维菌素耐药相关突变对 HIV-1 整合酶的药物敏感性和病毒复制适应性的影响。
Antimicrob Agents Chemother. 2013 Jun;57(6):2654-63. doi: 10.1128/AAC.02568-12. Epub 2013 Mar 25.
5
Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.鉴定 HIV-1 整合酶 R263K 突变，该突变赋予对第二代整合酶链转移抑制剂多替拉韦的低水平耐药性。
J Virol. 2012 Mar;86(5):2696-705. doi: 10.1128/JVI.06591-11. Epub 2011 Dec 28.
6
In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.体外使用艾维雷韦、拉替拉韦和艾维雷韦的两种代谢产物 M1 和 M4 进行耐药性选择。
Antiviral Res. 2012 Feb;93(2):288-296. doi: 10.1016/j.antiviral.2011.12.008. Epub 2011 Dec 16.
7
Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.与 HIV-1 对整合酶抑制剂耐药性发展相关的亚型多样性。
J Med Virol. 2011 May;83(5):751-9. doi: 10.1002/jmv.22047. Epub 2011 Feb 25.
8
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.成人HIV-1感染的抗逆转录病毒药物耐药性检测：美国国际艾滋病协会专家组2008年建议
Clin Infect Dis. 2008 Jul 15;47(2):266-85. doi: 10.1086/589297.
Zotero 插件